Koch, Elias A. T. ; Petzold, Anne ; Wessely, Anja 
; Dippel, Edgar ; Gesierich, Anja ; Gutzmer, Ralf ; Hassel, Jessica C. ; Haferkamp, Sebastian ; Kähler, Katharina C. ; Knorr, Harald ; Kreuzberg, Nicole ; Leiter, Ulrike ; Loquai, Carmen ; Meier, Friedegund ; Meissner, Markus ; Mohr, Peter ; Pföhler, Claudia ; Rahimi, Farnaz ; Schadendorf, Dirk ; Schell, Beatrice ; Schlaak, Max ; Terheyden, Patrick ; Thoms, Kai-Martin ; Schuler-Thurner, Beatrice ; Ugurel, Selma ; Ulrich, Jens ; Utikal, Jochen ; Weichenthal, Michael ; Ziller, Fabian ; Berking, Carola ; Heppt, Markus V.
; Dippel, Edgar ; Gesierich, Anja ; Gutzmer, Ralf ; Hassel, Jessica C. ; Haferkamp, Sebastian ; Kähler, Katharina C. ; Knorr, Harald ; Kreuzberg, Nicole ; Leiter, Ulrike ; Loquai, Carmen ; Meier, Friedegund ; Meissner, Markus ; Mohr, Peter ; Pföhler, Claudia ; Rahimi, Farnaz ; Schadendorf, Dirk ; Schell, Beatrice ; Schlaak, Max ; Terheyden, Patrick ; Thoms, Kai-Martin ; Schuler-Thurner, Beatrice ; Ugurel, Selma ; Ulrich, Jens ; Utikal, Jochen ; Weichenthal, Michael ; Ziller, Fabian ; Berking, Carola ; Heppt, Markus V. 
Abstract
Simple Summary The era of immune checkpoint blockade (ICB) with nivolumab and pembrolizumab (anti-PD-1) alone or in combination with ipilimumab (anti-CTLA-4) has led to prolonged survival in patients with cutaneous melanoma (CM). However, the response to ICB is low in patients with uveal melanoma (UM). This retrospective multicenter study examines the effectiveness of re-induction with ICB in ...
Owner only: item control page
Altmetric